(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.45%) $83.47
(-1.16%) $1.619
(-0.03%) $2 346.50
(0.74%) $27.46
(0.28%) $924.70
(-0.04%) $0.934
(-0.07%) $11.02
(-0.06%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services...
Stats | |
---|---|
Šios dienos apimtis | 529 130 |
Vidutinė apimtis | 1.60M |
Rinkos kapitalizacija | 7.88B |
EPS | INR0 ( 2024-02-13 ) |
Kita pelno data | ( INR0 ) 2024-05-27 |
Last Dividend | INR0.0500 ( 2020-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 97.64 |
ATR14 | INR0.0620 (0.18%) |
Tūris Koreliacija
Nectar Lifesciences Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Nectar Lifesciences Koreliacija - Valiuta/Žaliavos
Nectar Lifesciences Finansinės ataskaitos
Annual | 2022 |
Pajamos: | INR15.24B |
Bruto pelnas: | INR3.64B (23.91 %) |
EPS: | INR-1.080 |
FY | 2022 |
Pajamos: | INR15.24B |
Bruto pelnas: | INR3.64B (23.91 %) |
EPS: | INR-1.080 |
FY | 2022 |
Pajamos: | INR16.69B |
Bruto pelnas: | INR2.99B (17.94 %) |
EPS: | INR1.120 |
FY | 2021 |
Pajamos: | INR15.43B |
Bruto pelnas: | INR2.58B (16.69 %) |
EPS: | INR-3.27 |
Financial Reports:
No articles found.
Nectar Lifesciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR0.100 | 2006-02-01 |
Last Dividend | INR0.0500 | 2020-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | INR1.900 | -- |
Avg. Dividend % Per Year | 0.05% | -- |
Score | 1.38 | -- |
Div. Sustainability Score | 1.879 | |
Div.Growth Potential Score | 2.79 | |
Div. Directional Score | 2.34 | -- |
Year | Amount | Yield |
---|---|---|
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.0500 | 0.19% |
2019 | INR0.0500 | 0.24% |
2020 | INR0.100 | 0.81% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
REDINGTON.NS | Dividend Knight | 2023-07-06 | Annually | 18 | 3.28% | |
KPITTECH.NS | Dividend Knight | 2023-08-14 | Annually | 6 | 0.47% | |
FACT.NS | Dividend Junior | 2023-09-22 | Insufficient data to determine frequency | 2 | 0.09% | |
AMRUTANJAN.NS | Dividend Junior | 2023-09-14 | Semi-Annually | 15 | 0.38% | |
TASTYBITE.NS | Dividend Junior | 2023-07-14 | Annually | 8 | 0.01% | |
NH.NS | Dividend Junior | 2023-07-06 | Sporadic | 6 | 0.14% | |
IMPAL.NS | Dividend Junior | 2023-07-20 | Annually | 19 | 1.79% | |
CHEVIOT.NS | Dividend Junior | 2023-08-03 | Annually | 3 | 1.62% | |
SALASAR.NS | Dividend Junior | 2023-09-15 | Annually | 8 | 1.41% | |
LUPIN.NS | Dividend Junior | 2023-07-14 | Annually | 23 | 0.37% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00493 | 1.500 | 9.90 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.00754 | 1.500 | -1.027 | -1.541 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.093 | 1.000 | -0.706 | -0.706 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.43 | 2.00 | 8.19 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.43 | 2.00 | 7.29 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.251 | 1.000 | 9.14 | 9.14 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0553 | 1.000 | -0.893 | -0.893 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.879 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 98.05 | 1.000 | 0.197 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00754 | 2.50 | -0.660 | -1.541 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.43 | 2.00 | 8.19 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.43 | 2.00 | 8.19 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.730 | 1.500 | 8.46 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0746 | 1.000 | -0.635 | 0 | [0.1 - 0.5] |
Total Score | 2.79 |
Nectar Lifesciences
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.